ESC Report 2014: Long-term efficacy and safety of alirocumab for lowering cholesterol
Report from the ESC Annual Congress by Bruce Sylvester: The investigational monoclonal antibody alirocumab, which significantly lowers cholesterol on top of regular statin therapy, also lowers the incidence… read more.